North America Radiopharmaceuticals Market- Advancing Diagnostics and Targeted Therapies Through Innovation and Growing Healthcare Demand | Market Players: Siemens AG, Positron Corporation, Curium, GE Healthcare among others

Radiopharmaceuticals Market size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate CAGR of 6.2% over the forecast period 2024-2031.
The radiopharmaceuticals market focuses on the development, production, and distribution of radioactive compounds used in medical diagnostics and therapy. These compounds, administered through injection, ingestion, or inhalation, are tracked using imaging techniques like PET and SPECT. Radiopharmaceuticals play a key role in diagnosing and treating diseases such as cancer, cardiovascular conditions, and neurological disorders, offering precise, non-invasive methods for detection and treatment. The market is driven by advancements in nuclear medicine, growing demand for personalized medicine, and increased applications in oncology, cardiology, and neurology, contributing to its significant growth.

Download Free Sample PDF: https://www.datamintelligence.com/download-sample/radiopharmaceuticals-market?ophp

The North America radiopharmaceuticals market is experiencing robust growth, with a valuation of around $3.2 billion in 2023 and projected to reach approximately $8.4 billion by 2033 at a CAGR of 10.2%. The United States leads this growth due to its advanced healthcare infrastructure, rising prevalence of chronic diseases such as cancer and cardiovascular conditions, and rapid technological advances in imaging techniques like PET and SPECT. Additionally, supportive regulatory policies and increasing awareness about nuclear medicine are driving demand for both diagnostic and therapeutic radiopharmaceuticals, positioning North America as a key player in this dynamic market landscape.

Growth Drivers:

The increasing prevalence of diseases like cancer and cardiovascular conditions is expected to drive market growth in the coming years. According to data from the National Cancer Institute in October 2020, researchers have developed and tested radiopharmaceuticals for various cancers, including lung, melanoma, colorectal, and leukemia. Additionally, researchers have repurposed targeting molecules, such as Lutetium Lu 177, to carry more potent radioactive compounds or isotopes that can directly kill cancer cells, rather than just assist with visualization. Prostate cancer, for example, has been a primary area for this repurposing, as PSMA is found in high quantities almost exclusively on prostate cells. A molecule that binds to PSMA is fused with a radioactive compound for use in PET scan imaging.

Customize Your Scope: https://www.datamintelligence.com/customize/radiopharmaceuticals-market?ophp

Market Segments

By Radioisotopes the market is sub segmented as Tec.99, F18, Iodine 131, Lutetium 177, Yttrium 90, Gallium 68, Gallium 67, Rubidium 82, Iodine 123, Iodine 125, Indium 111, Others

By Application the market is classified as Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others

By Source the market is further divided as Cyclotrons, Nuclear Reactor

By End User the market is bifurcated into Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Cancer Research Institute

Key Players:
• Siemens AG
• Positron Corporation
• Curium
• GE Healthcare
• Lantheus Holdings Inc.
• Sotera Health LLC
• Bayer AG
• Eckert & Ziegler
• Novartis AG
• BWX Technologies Inc.

Regional Analysis
North America holds the largest share of the global radiopharmaceuticals market and is expected to maintain this dominance through the forecast period (2022-2029). The region's significant market size is driven by the increasing prevalence of cancer and other diseases, advanced healthcare infrastructure, new product launches, and the presence of key industry players. According to the Centers for Disease Control and Prevention, as of July 2022, around 20.1 million adults aged 20 and older are affected by coronary artery disease (CAD), representing approximately 7.2% of the population. This growing disease burden fuels the demand for effective treatments in North America.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=radiopharmaceuticals-market

Key Developments:

Telix Pharmaceuticals' Product Launches and Expansion (January 16, 2025)

Telix Pharmaceuticals reported a 55% revenue growth in 2024 and plans significant expansion in 2025 with the expected U.S. launch of three new radiopharmaceutical products, pending FDA approval. These include Gozellix for prostate cancer, Pixclara for glioblastoma, and Zircaix for kidney cancer, with PDUFA dates set for March, April, and August/September 2025. The company also aims to expand the approval of its leading product, Illuccix, for prostate cancer imaging into key international markets like the EU, UK, and Brazil.

Y-mAbs Strategic Business Update (January 10, 2025)

Y-mAbs Therapeutics has set strategic priorities for 2025, focusing on advancing its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA. The company plans to establish two business units dedicated to its radiopharmaceutical pipeline and expects Phase 1 trial data for GD2-SADA in Q2 2025, with the first patient for the CD38-SADA trial dosed in Q1 2025. Additionally, Y-mAbs aims to expand DANYELZA's approval into new ex-U.S. markets by 2025, broadening its global impact in oncology.

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.